Key Points
- Elanco director Lawrence Erik Kurzius bought 40,000 shares at an average price of $23.40, investing $936,000 and increasing his holdings by 26.91% to 188,647 shares.
- Elanco reported quarterly EPS of $0.34, beating estimates of $0.27, while revenue reached $1.37 billion and rose 10.2% year over year. The company issued full-year 2026 EPS guidance of $1.10–$1.16.
- Analysts maintain a generally positive outlook, with a consensus “Moderate Buy” rating and an average price target of $29.09, versus the stock’s recent price near $24.05.
Elanco Animal Health Incorporated (NYSE:ELAN - Get Free Report) Director Lawrence Erik Kurzius bought 40,000 shares of the stock in a transaction that occurred on Thursday, August 20th. The shares were purchased at an average price of $23.40 per share, for a total transaction of $936,000.00. Following the purchase, the director owned 188,647 shares in the company, valued at $4,414,339.80. This represents a 26.91% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
Elanco Animal Health Trading Up 2.1%
Shares of Elanco Animal Health stock opened at $24.05 on Friday. Elanco Animal Health Incorporated has a fifty-two week low of $17.11 and a fifty-two week high of $27.98. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.10 and a current ratio of 2.05. The company has a market capitalization of $12.02 billion, a P/E ratio of -58.66, a P/E/G ratio of 1.41 and a beta of 1.67. The company has a fifty day moving average of $24.56 and a 200 day moving average of $24.01.
Elanco Animal Health (NYSE:ELAN - Get Free Report) last posted its quarterly earnings results on Wednesday, August 5th. The company reported $0.34 EPS for the quarter, beating analysts' consensus estimates of $0.27 by $0.07. The business had revenue of $1.37 billion for the quarter, compared to analysts' expectations of $1.31 billion. Elanco Animal Health had a positive return on equity of 8.13% and a negative net margin of 3.96%.The business's quarterly revenue was up 10.2% on a year-over-year basis. During the same period last year, the firm earned $0.26 earnings per share. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. On average, sell-side analysts anticipate that Elanco Animal Health Incorporated will post 1.12 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Elanco Animal Health
Large investors have recently modified their holdings of the stock. NewEdge Advisors LLC raised its holdings in Elanco Animal Health by 133.7% during the 4th quarter. NewEdge Advisors LLC now owns 1,096 shares of the company's stock valued at $25,000 after buying an additional 627 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new position in Elanco Animal Health during the second quarter worth $38,000. Root Financial Partners LLC increased its position in Elanco Animal Health by 50.7% during the fourth quarter. Root Financial Partners LLC now owns 1,759 shares of the company's stock valued at $40,000 after acquiring an additional 592 shares during the last quarter. Uniplan Investment Counsel Inc. bought a new position in Elanco Animal Health during the fourth quarter valued at $41,000. Finally, Torren Management LLC bought a new position in Elanco Animal Health during the fourth quarter valued at $46,000. Institutional investors own 97.48% of the company's stock.
Wall Street Analysts Forecast Growth
A number of research analysts recently commented on ELAN shares. Citigroup boosted their price target on Elanco Animal Health from $30.00 to $31.00 and gave the stock a "buy" rating in a report on Thursday, May 7th. UBS Group increased their price objective on shares of Elanco Animal Health from $31.00 to $33.00 and gave the company a "buy" rating in a report on Thursday, August 6th. Morgan Stanley lifted their price objective on shares of Elanco Animal Health from $23.00 to $26.00 and gave the company an "equal weight" rating in a research report on Wednesday, July 22nd. Weiss Ratings cut shares of Elanco Animal Health from a "sell (d+)" rating to a "sell (d)" rating in a research report on Thursday. Finally, Piper Sandler reissued an "overweight" rating on shares of Elanco Animal Health in a report on Monday, June 29th. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Elanco Animal Health has an average rating of "Moderate Buy" and a consensus target price of $29.09.
Check Out Our Latest Report on ELAN
Elanco Animal Health Company Profile
(
Get Free Report)
Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco's portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.
Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
